| Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 F Meng, JW Evans, D Bhupathi, M Banica, L Lan, G Lorente, JX Duan, ... Molecular cancer therapeutics 11 (3), 740-751, 2012 | 228 | 2012 |
| Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia CP Guise, AM Mowday, A Ashoorzadeh, R Yuan, WH Lin, DH Wu, ... Chinese journal of cancer 33 (2), 80, 2014 | 199 | 2014 |
| Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility EM Williams, RF Little, AM Mowday, MH Rich, JVE Chan-Hyams, ... Biochemical journal 471 (2), 131-153, 2015 | 142 | 2015 |
| Engineering a multifunctional nitroreductase for improved activation of prodrugs and PET probes for cancer gene therapy JN Copp, AM Mowday, EM Williams, CP Guise, A Ashoorzadeh, ... Cell Chemical Biology 24 (3), 391-403, 2017 | 73 | 2017 |
| Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A GA Prosser, JN Copp, AM Mowday, CP Guise, SP Syddall, EM Williams, ... Biochemical pharmacology 85 (8), 1091-1103, 2013 | 59 | 2013 |
| Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy Z Fu, AM Mowday, JB Smaill, IF Hermans, AV Patterson Cells 10 (5), 1006, 2021 | 56 | 2021 |
| Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954 PM Swe, JN Copp, LK Green, CP Guise, AM Mowday, JB Smaill, ... Biochemical pharmacology 84 (6), 775-783, 2012 | 37 | 2012 |
| Advancing clostridia to clinical trial: past lessons and recent progress AM Mowday, CP Guise, DF Ackerley, NP Minton, P Lambin, LJ Dubois, ... Cancers 8 (7), 63, 2016 | 33 | 2016 |
| Selectively targeting tumor hypoxia with the hypoxia-activated prodrug CP-506 AMA van der Wiel, V Jackson-Patel, R Niemans, A Yaromina, E Liu, ... Molecular Cancer Therapeutics 20 (12), 2372-2383, 2021 | 27 | 2021 |
| Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy AM Mowday, A Ashoorzadeh, EM Williams, JN Copp, S Silva, MR Bull, ... Biochemical Pharmacology 116, 176-187, 2016 | 23 | 2016 |
| Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy LK Green, SP Syddall, KM Carlin, GD Bell, CP Guise, AM Mowday, ... Molecular cancer 12, 1-6, 2013 | 19 | 2013 |
| E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications AM Mowday, JN Copp, SP Syddall, LJ Dubois, J Wang, NG Lieuwes, ... Theranostics 10 (23), 10548, 2020 | 16 | 2020 |
| Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug … EM Williams, MH Rich, AM Mowday, A Ashoorzadeh, JN Copp, CP Guise, ... Biochemistry 58 (35), 3700-3710, 2019 | 12 | 2019 |
| Use of a luciferase-expressing orthotopic rat brain tumor model to optimize a targeted irradiation strategy for efficacy testing with temozolomide AM Mowday, NG Lieuwes, R Biemans, D Marcus, B Rezaeifar, B Reniers, ... Cancers 12 (6), 1585, 2020 | 11 | 2020 |
| Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours AM Mowday, LJ Dubois, AM Kubiak, JVE Chan-Hyams, CP Guise, ... Cancer Gene Therapy 29 (2), 178-188, 2022 | 10 | 2022 |
| Bacterial nitroreductase enzymes and methods relating thereto CP Guise, DF Ackerley, A Ashoorzadeh, JN Copp, JU Flanagan, ... US Patent 10,357,577, 2019 | 6 | 2019 |
| Compounds and methods for selective imaging and/or ablation RF Anderson, JB Smaill, AV Patterson, A Ashoorzadeh, DF Ackerley, ... US Patent App. 14/368,261, 2015 | 6 | 2015 |
| Restoring tumour selectivity of the bioreductive prodrug PR-104 by developing an analogue resistant to aerobic metabolism by human aldo-keto reductase 1C3 MR Abbattista, A Ashoorzadeh, CP Guise, AM Mowday, R Mittra, S Silva, ... Pharmaceuticals 14 (12), 1231, 2021 | 5 | 2021 |
| Kinase inhibitors, prodrug forms thereof and their use in therapy JB Smaill, AV Patterson, GL Lu, HH Lee, A Ashoorzadeh, RF Anderson, ... US Patent 9,101,632, 2015 | 4 | 2015 |
| Prodrugs and methods of use thereof JB Smaill, AV Patterson, A Ashoorzadeh, CP Guise, AM Mowday, ... US Patent 10,202,408, 2019 | 3 | 2019 |
